Key result
Beta blocker treatment was associated with a reduced risk of total mortality (HR 0.66; 95% CI 0.48-0.90) in patients with clinical evidence of heart failure after myocardial infarction.
Why the study?
Does beta blocker treatment reduce total mortality and progression to severe heart failure in patients with clinical evidence of heart failure after acute myocardial infarction?
Population
Patients with clinical evidence of mild to moderate heart failure after acute myocardial infarction.
Comparison
Beta blocker treatment vs No beta blocker treatment
Design
Cohort
Authors
Loading...
Supports the use of beta blockers in post-MI heart failure; leaves open whether this observational survival benefit.
Observational
Does beta blocker treatment reduce total mortality and progression to severe heart failure in patients with clinical evidence of heart failure after acute myocardial infarction?
Effect estimate: HR 0.66 (95% CI 0.48-0.90)
Beta blocker treatment is associated with significantly improved outcomes, including reduced mortality and progression to severe heart failure, in patients with clinical evidence of heart failure post-myocardial infarction.
Spargias et al. (1999) conducted an observational in Heart failure after myocardial infarction. Beta blocker vs. No beta blocker was evaluated on Total mortality (HR 0.66, 95% CI 0.48-0.90). Beta blocker treatment was associated with a reduced risk of total mortality (HR 0.66; 95% CI 0.48-0.90) in patients with clinical evidence of heart failure after myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: